A general claim about creatine is usually a claim about men. Not because anyone said so, but because that is who was enrolled. This page counts. This is research journalism and contains no usage guidance, per our editorial standards.
The census
PubMed indexes the sex of enrolled participants, which makes the question answerable rather than arguable. Searched on 2026-09-11, restricted to randomised controlled trials in humans of creatine supplementation — excluding the much larger literature where "creatine kinase" appears as a laboratory marker.
| Trials indexed as | Count | Share |
|---|---|---|
| Male only | 202 | 48.4% |
| Female only | 37 | 8.9% |
| Both sexes | 158 | 37.9% |
| Neither tag recorded | 20 | 4.8% |
| Total | 417 |
Male-only trials outnumber female-only trials 5.5 to one, and nearly half the literature enrolled no women whatsoever.
The wider, unfiltered set behaves the same way. All 2,788 randomised controlled trials matching creatine in humans — a set inflated by creatine-kinase papers, which is why the narrower count above is the one to quote — divide into 769 male-only, 115 female-only and 1,596 mixed: a ratio of 6.7 to one in the same direction.
A methodological note, since this site asks it of others: the two scales are not interchangeable and should never be mixed in a sentence. The 417 is the supplementation literature; the 2,788 is everything the word touches. Both were re-derived in this session against a control query returning 149 records, matching this site's previous count.
Where the loading protocol came from
The same asymmetry runs all the way down to the instructions on the tub. The two studies that established creatine loading enrolled 48 subjects between them — 17 in the 1992 biopsy study and 31 in the 1996 follow-up — and every one was male. The 1996 paper does not leave it to be inferred; its title is "Muscle creatine loading in men" (PMID 8828669).
Whether women saturate at the same rate, hold the elevation on the same maintenance amount, or wash out over the same thirty days has not been established by those papers, because those papers could not establish it.
What the female evidence does show
It is small, recent, and better than the census would lead you to expect.
The strongest single piece is a 2026 systematic review and meta-analysis of randomised placebo-controlled trials of creatine in postmenopausal women, searched across six databases from 2000 to August 2025 (PMID 42141930). Seven trials, 608 randomised, durations of 12 to 104 weeks with a median of 38, mean age approximately 62.
| Outcome | Trials | n | Result |
|---|---|---|---|
| Lean mass (DXA) | 5 | 338 | +0.37 kg (95% CI +0.05 to +0.69), I² = 25% |
| Leg-press 1RM | 3 | 111 | +7.5 kg (95% CI +2.2 to +12.8), I² = 0% |
| Bone mineral density | — | — | Unchanged overall |
Two things deserve to be said about these numbers rather than around them.
The strength result is the more solid of the two. An I² of zero means the three trials agreed with each other, and the confidence interval excludes no benefit by a clear margin. Leg-press one-repetition maximum is also a specific, measurable thing rather than a composite.
The lean-mass result is weaker than its confidence interval suggests. The authors also report a 95% prediction interval of −0.10 to +0.84, which crosses zero — meaning that on their own modelling, a future trial in a new population could plausibly find no effect at all. A prediction interval is the honest statistic for asking what happens next, and it is the one most summaries omit.
The authors' own subgroup finding is that benefits appeared where at least 5 g a day was combined with resistance training, while trials at 3 g a day or less without resistance training showed no measurable effect. Adverse events were mild and similar to placebo, and renal indices were unchanged — consistent with the wider safety record. Risk of bias was mostly rated "some concerns", with one large preregistered double-blind trial at low risk.
What is still missing
Almost everything about younger and trained women. The meta-analysable base is postmenopausal, mean age 62, and the outcomes that population was studied for — lean mass preservation, leg strength, bone density — are not the outcomes a 25-year-old lifter is asking about.
There is also a hypothesis the census makes hard to test. Differences in baseline muscle creatine, in hormonal environment across the menstrual cycle, and in response to the same amount per kilogram have all been proposed as reasons women might respond differently. With 37 female-only trials to draw on, spread across decades, populations and outcomes, none of those proposals has the evidence behind it to be confirmed or dismissed.
The question is old enough to have been formally catalogued. The International Society of Sports Nutrition's 2021 review of common creatine questions lists "Is creatine only useful for males?" as question 11 of 12 (PMID 33557850) — and the authors of that review disclose extensive creatine-industry relationships, which we note here for the same reason we note it on the efficacy literature.
The honest summary
- Nearly half of creatine supplementation trials enrolled no women.
- Male-only trials outnumber female-only trials 5.5 to one.
- The loading protocol on every label was established in 48 men.
- In postmenopausal women, seven trials and 608 participants show small, real gains in lean mass and leg strength, with bone density unchanged and a lean-mass prediction interval that crosses zero.
- For trained younger women, the evidence is thin enough that anyone claiming certainty is extrapolating from men.
That is not an argument that creatine does not work for women. It is an argument that the confidence with which the general claim is usually stated does not match the population it was measured in — which is the same test this site applies to the compounds sold at forty times the price, and it should not be applied more gently to a supplement because the supplement is cheap and legal.
Sources and dates
All PubMed searches run 2026-09-11 via E-utilities; sex tagging from MeSH male[mh] / female[mh]. Control query minoxidil AND alopecia AND "randomized controlled trial"[pt] returned 149, reproducing this site's previous count.
| Source | What it supplied |
|---|---|
| PubMed sex census, 417 supplementation RCTs, 2026-09-11 | 202 male-only, 37 female-only, 158 both, 20 untagged |
| PubMed sex census, 2,788 unfiltered RCTs, 2026-09-11 | 769 / 115 / 1,596 / 308, the 6.7-to-one ratio |
| Postmenopausal meta-analysis, J Int Soc Sports Nutr 2026, PMID 42141930 | 7 trials, 608 women, lean mass, leg-press 1RM, prediction interval, bone density |
| Hultman et al., J Appl Physiol 1996;81(1):232–7, PMID 8828669 | 31 male subjects; "in men" |
| Harris et al., Clin Sci 1992;83(3):367–74, PMID 1327657 | 17 subjects in the original biopsy study |
| Antonio et al., J Int Soc Sports Nutr 2021;18(1):13, PMID 33557850 | The twelve standing questions, including question 11 |
Figures are reported as the sources state them. Nothing here is a recommendation or an instruction.